CCI observation to keep Sun-Ranbaxy in focus

| Updated on December 02, 2014 Published on December 02, 2014


Analysts expect the proposed merger of Sun Pharmaceutical Industries and Ranbaxy Laboratories to get green signal from the Competition Commission of India in the next few days. But they expect the watchdog may clear the deal, but will ask the companies to make some changes in the original deal. On April 6, Sun Pharma had announced it would buy Ranbaxy from Daiichi Sankyo in an all-share deal pegged at $4 billion.

Published on December 02, 2014
This article is closed for comments.
Please Email the Editor